Companies ›Health Care ›POM.O

POM.O — NASDAQ Pharmaceuticals

PomDoctor Ltd

$0,89

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

106,3M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,86

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

PomDoctor Ltd has a market capitalization of $13,969,602.43, with a market price of $0.1172 per share, based on the latest valuation data. The company's capital structure is characterized by a lack of detailed balance-sheet inputs, which limits the ability to assess liquidity risk comprehensively. Profitability and return metrics for PomDoctor are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or cohort medians. This absence of data also hinders the evaluation of key financial ratios such as return on invested capital (ROIC) and operating margins. The company's revenue concentration and geographic exposure are not disclosed in the available data, which limits the ability to assess the diversification of its revenue streams or the risks associated with geographic concentration. Growth trajectory data is limited, with no specific numeric deltas or revenue history provided for the current or next fiscal year. This lack of data makes it challenging to project future performance or assess the company's growth potential. Risk factors for PomDoctor include the inability to assess liquidity risk due to the absence of bal

Business. PomDoctor Ltd (POM.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score→

composite score

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability

—

not yet wired

Quality→

quality score (0-100)

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning POM.

Sector rotation

Sector1D1Mvs mkt

Communication Services+2,2 %−5,5 %+1,5 %

Materials+2,2 %+3,1 %+1,5 %

Energy+0,9 %+5,2 %+0,1 %

Health Care · THIS SECTOR+0,7 %−1,2 %+0,0 %

Consumer Discretionary+0,3 %+9,2 %−0,4 %

Information Technology+0,1 %+8,1 %−0,6 %

Financials−0,5 %−3,0 %−1,2 %

Consumer Staples−0,6 %+3,3 %−1,4 %

Real Estate−0,7 %+10,8 %−1,4 %

Industrials−1,1 %−0,3 %−1,8 %

Utilities−1,9 %+28,2 %−2,6 %

Developing storylines

No tracked sagas currently linked to POM.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-07-23 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Composite score27 / 100

Composite score 0-100 · Data quality 0,50

Data quality0,50 / 1.00

Synthesis

Business

PomDoctor Ltd (POM.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

Profitability and return metrics for PomDoctor are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or cohort medians. This absence of data also hinders the evaluation of key financial ratios such as return on invested capital (ROIC) and operating margins.

The company's revenue concentration and geographic exposure are not disclosed in the available data, which limits the ability to assess the diversification of its revenue streams or the risks associated with geographic concentration.

Growth trajectory data is limited, with no specific numeric deltas or revenue history provided for the current or next fiscal year. This lack of data makes it challenging to project future performance or assess the company's growth potential.

Risk factors for PomDoctor include the inability to assess liquidity risk due to the absence of balance-sheet inputs and no going-concern language in the source documents. The dilution risk is currently rated as low, with no immediate pressure for additional share issuance.

Recent events and filings for PomDoctor are not detailed in the available data, which limits the ability to assess any recent developments that may impact the company's financial position or strategic direction.

Key takeaways

PomDoctor Ltd operates in the pharmaceuticals and medical research sector with a classification confidence of 0.92.
The company's market capitalization is $13,969,602.43, with a market price of $0.1172 per share.
Detailed financial metrics such as profitability and return ratios are not available, limiting the ability to compare against industry benchmarks.
The company's liquidity risk cannot be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.
Dilution risk is currently rated as low, with no immediate pressure for additional share issuance.
**margin_outlook_rationale**: Insufficient data to determine the direction of margin changes.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$0,89

Market cap

$14.0M

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures

Partners1

Focus Media Information Te002027.SZPartner90%Source ↗

Supply chain

Vendors → POM ↔ Partners → Customers · click any node to drill

1 mention in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison8 peers · vs POM · multiples and returns

MCK—

Mckesson Corp

$828,84

102,9B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

— vs self

COR—

Cencora Inc

$303,53

58,9B USD

P/E

35,5x

— vs self

Div yield

0,7 %

— vs self

ROE

103,1 %

— vs self

CAH—

Cardinal Health Inc

$226,09

54,7B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

— vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$675,19

72,7B USD

P/E

14,9x

— vs self

Div yield

—

— vs self

ROE

14,3 %

— vs self

BIIB—

BIOGEN INC.

$203,02

29,8B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

— vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,71

2,0B USD

P/E

5,3x

— vs self

Div yield

2,1 %

— vs self

ROE

7,6 %

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

PomDoctor Ltd Market data — financials · 2026-05-29

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Insider activity

— missing data

Short positioning

74.4Kshares short-83.3% vs prior

1days to cover

32.8%short of daily vol

4.0Kfails-to-deliver

as of 2026-06-30 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

POM.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

Debt-to-equity (FY 2025-12-31): -1.30xDerived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 25.2%Derived (calculated)
Gross margin (FY 2025-12-31): 13.1%Derived (calculated)
Current ratio (FY 2025-12-31): 0.48xDerived (calculated)
Cost of revenue (annual): USD 49.71MSEC XBRL filing
Current liabilities (annual): USD 31.2MSEC XBRL filing
Revenue (annual): USD 57.19MSEC XBRL filing
Shareholders' equity (annual): USD -64.92MSEC XBRL filing
Operating cash flow (annual): USD -21.23MSEC XBRL filing
Total assets (annual): USD 15.38MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -3SEC XBRL filing
Gross profit (annual): USD 7.48MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -3SEC XBRL filing
R&D expense (annual): USD 1.84MSEC XBRL filing
Current assets (annual): USD 15.01MSEC XBRL filing
Total liabilities (annual): USD 84.21MSEC XBRL filing
Long-term debt (annual): USD 11.7MSEC XBRL filing
Cash & equivalents (annual): USD 1.37MSEC XBRL filing
Pre-tax income (annual): USD -18.72MSEC XBRL filing
Capex (annual): USD 144.11KSEC XBRL filing
Operating income (annual): USD -16.96MSEC XBRL filing
Total operating expenses (annual): USD 24.44MSEC XBRL filing
Cash & equivalents (annual): USD 1.09MSEC XBRL filing

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-06-17FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-05-28FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-05-14FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-05-14FILINGANNUAL REPORT →

2026-04-20FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-04-08FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-02-04FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-02-02FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-01-16FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-12-03FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-10-09FILINGPROSPECTUS →

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-23 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread